In Russia, as in Western markets, polypharmacy plays a critical role in the management of patients with acute coronary syndrome (ACS), a factor which has led to development of a broad treatment armamentarium of multinational corporation (MNC) brand and generic drugs in this country. Through the 2012-2017 period, additional entries will expand the Russian ACS market both in total patient share percentage and sales. However, factors such as drug price controls and an average monthly income that limits patients’ accessibility to drugs paid out-of-pocket will temper ACS market growth potential.
Primary research: 90 cardiologist surveys across Russia. Separate in-depth interviews with 8 cardiologists.
Epidemiology: Diagnosed ACS events: total; by age-group; by ACS subtype. Drug-treated ACS events. Drug-treated incident ACS cases that have survived 12 months. Ten-year epidemiology forecasts through 2022.
Market forecast features: Our analysis evaluates the size of the population with access to medical care, rates of diagnosis of ACS, and rates of drug treatment. We include a detailed forecast for ACS drug classes and leading products for the 2012-2017 period using an epidemiology-based, bottom-up market model.